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Objectives: Cytokeratin 19 is signiﬁcant for indicating cancer cells, and Cyfra 21-1 is a fragment of
cytokeratin 19. This retrospective study was designed to deﬁne the prognostic value of serum Cyfra 21-1
in epithelial ovarian cancers (EOC).
Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to
treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The
standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis.
Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retro-
peritoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0 ng/mL as the cut-off)
were associated with shorter disease-free survival (16 months vs. 28 months, p ¼ 0.001) and overall
survival (29 months vs. 41 months, p¼ 0.007) than lower levels. Further univariable analysis showed that
Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum
resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and
serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival.
Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic signiﬁcance for EOC,
indicating poor survival when it was elevated above 3.0 ng/mL.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer (EOC) is the second most common
gynecologic malignancy and most common cause of death among
women with gynecologic cancers [1,2]. The standard treatment for
EOC is extensive surgical resection of the primary tumor and all
visible tumors in the abdominal cavity, followed by postoperative
adjuvant carboplatin and paclitaxel chemotherapy with/without
targeted therapy [3e5]. Although adjuvant postoperative chemo-
therapy with cytotoxic drugs allows nearly all patients with EOC to
achieve complete clinical remission, the disease-free interval isd Gynecology, Taipei Medical
, Zhonghe District, New Taipei
.
bstetrics & Gynecology. Publishedshort and often transient [6]. Analyses of prognostic factors shows
that massive ascites, poor differentiation, lymph node metastases,
advanced stage, suboptimal debulking surgery, chemo-resistance,
and poor performance status contributes to tumor recurrence and
disease-related death. Therefore, preoperative evaluation, using
imaging, or serum tumor markers to predict the above-mentioned
prognostic factors is important. Deﬁning a serummarker to predict
prognosis seems to be a very simple but important method at
present to guide the therapeutic plan. Among the serum markers,
serum cancer antigen (CA)125 is well known and has been used for
long time; it has been considered the “gold standard” for moni-
toring therapy, indicating optimal surgery and response to
chemotherapy [7,8]. Besides, the speciﬁcity of the serum CA125
level seems to be low, because it is elevated in many nonspeciﬁc
conditions [9e12], including inﬂammatory disease, endometriosis,
benign tumors, menstruation, and cirrhosis of the liver. However, a
consensus has not yet been reached in predicting prognosis andby Elsevier Taiwan LLC. All rights reserved.
Table 1
Serum cytokeratin19 fragment (Cyfra 21-1) and cancer antigen (CA125), and the
clinicopathologic parameters.
Cyfra 21-1 (ng/mL) CA125 (U/mL)
Mean SD n pa Mean SD n pa
Age
<50 y 7.09 16.66 19 0.104 300.51 299.85 15 0.018
50 y 16.16 18.35 23 187.12 2415.49 19
Histology
Serous 24.97 27.35 12 0.002 2377.00 3045.72 10 0.019
Nonserous 6.89 6.89 30 678.74 1002.48 24
Ascites
Yes 21.53 14.23 23 0.020 1934.38 2387.38 21 0.196
No 4.70 6.29 19 743.51 1426.18 13
Grade
1 3.43 6.45 5 0.524 78.45 62.23 4 0.395
2 12.76 22.43 20 1577.07 2262.08 15
3 13.77 13.92 17 1072.65 1850.08 15
LN metastasis
Yes 21.83 24.69 15 0.010 1955.92 2176.91 15 0.022
No 4.67 6.89 24 377.09 807.55 19
Optimal surgery
Yes 5.49 6.84 28 0.001 766.85 1292.55 23 0.181
No 26.92 25.55 13 2075.45 2804.04 11
Recurrence
Yes 17.89 21.50 24 0.013 2362.81 528.34 19 0.299
No 4.28 6.52 18 1130.36 302.10 15
Death
Yes 22.19 21.882 13 0.013 1959.93 2872.55 11 0.109
No 7.51 14.16 29 804.36 1252.42 23
Platinum resistance
Yes 37.32 22.19 6 <0.001 3203.00 3507.15 6 0.004
No 7.85 13.45 36 744.34 1148.11 28
a The p value was calculated using one-way analysis of variance method.
Table 2
Preoperative serum cytokeratin19 fragment (Cyfra 21-1) and cancer antigen (CA)125
levels divided by different cut-off values and their associations with disease-free
survival and overall survival.
Disease-free survival Overall survival
Median SEM pa Median SEM pa
Cyfra 21-1
<1.9 ng/mL 28 6 0.059 32 5 0.183
1.9 ng/mL 16 3 30 2
Cyfra 21-1 (3.0)
<3.0 ng/mL 28 5 0.001 41 7 0.007
3.0 ng/mL 16 4 29 23
CA125
<35 18 10 0.573 32 18 0.341
35 18 1 31 2
CA125
<100 31 19 0.082 34 3 0.232
100 16 4 30 4
SEM ¼ standard error of the mean.
a The p value was calculated using the log rank test.
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combinations of these markers have been used to try to identify
patients who will beneﬁt from standard treatment; some of them
are potential candidates, including HE4 [15].
Since the 1990s, Cyfra 21-1, a fragment of cytokeratin 19 (CK19),
has been introduced as a potential marker for monitoring various
kinds of cancers, including breast [16,17], liver [18], lung [19,20],
thyroid [21], urinary bladder [22], esophageal squamous cell carci-
noma [23], colorectal [24], undifferentiated nasopharyngeal carci-
noma [25], squamous cell carcinoma of the cervix [26], and ovarian
[27,28]. In the study of nonesmall-cell lung cancer and breast can-
cer, CK19 was shown to be a better alternative marker than other
markers [16,17,19,20]. In addition, CK19 is also an effective and sig-
niﬁcant marker for detecting circulation cancer cells [29]. Serum
CK19 has been reported infrequently in ovarian cancer, with a
sensitivity of 33e61.3%, but a speciﬁcity of 95%, showing it is not
endometriosis-related [30]. Using immunohistochemistry and a
monoclonal antibody against CK19 produced in our laboratory [31],
89% of the ovarian epithelial cancer tissues showed positive (un-
published data). However, the prognostic role of CK19 has not been
deﬁned clearly. CK19 was previously recognized as an activator of
proteolytic enzymes caspase 3 during cell apoptosis [32]; however,
recent reports showed that CK19might represent active, proliferative
tumor cells, and it was suggested to be a marker for progenitor/stem
cells [33,34] and related to the oncogenesis of cancers [35]. Because
CK19 has such potential as an upstream marker for cancer develop-
ment, it seems worthy of further extensive investigation in various
aspects as a tumor marker for ovarian cancer.
To deﬁne the prognostic role of serum Cyfra 21-1 in ovarian
cancers, especially when compared to the gold standard marker,
CA125, we conducted this study aimed at various clinicopathologic
factors, response to chemotherapy, and survival.
Patients and methods
Patients and clinicopathologic variables
Serum samples were collected preoperatively from all patients
suspected of having ovarian malignancies and sent to the central
laboratory of Taipei Veterans General Hospital, Taipei, Taiwan for
measurement of a series of tumor markers, including Cyfra 21-1
and CA125. Forty-two patients with EOC conﬁrmed by pathology
were included. Staging was based on the International Federation
of Gynecology and Obstetrics criteria. Various clinicopathologic
factors were recorded, including age, presence of ascites, tumor
stage, histological type, differentiation, retroperitoneal lymph node
metastasis, the largest diameter of the residual tumor, platinum-
resistance, and time to recurrence and/or death. The presence of
ascites was deﬁned as a ﬁnding of>100 mL of intraperitoneal ﬂuid.
The standard primary staging surgery consisted of peritoneal
washing cytology, total hysterectomy, bilateral adnexectomy, ap-
pendectomy, and infracolic omentectomy. Optimal surgery was
deﬁned as a tumor with a greatest diameter of <1 cm. Post-
operative treatment consisted of six courses of paclitaxel plus car-
boplatin. Patients were followed-up every 3months during the ﬁrst
2 years, then every 6 months thereafter. The median follow-up
duration in this study was 31.5 months (range, 1e62 months).
Clinical recurrence was deﬁned by positive ﬁndings in the
physical examination, imaging, and elevated serum CA125 levels.
Platinum-resistance was deﬁned as a clinical recurrence occurring
within 6 months after completion of ﬁrst-line chemotherapy.
Disease-free survival (DFS) was measured from the date of the
initial laparotomy to the date of recurrence or metastasis. Overall
survival (OS) was measured to the date of death or latest follow-up.
No patients in this study were lost to follow-up.Measurement and evaluation of serum Cyfra 21-1 and CA125 levels
Preoperative serum levels of Cyfra 21-1 were determined by a
solid-phase “sandwich” immunoradiometric method (CIS Bio In-
ternational, Gif-sur-Yvette, France) in the radioimmunoassay lab-
oratory of Taipei Veterans General Hospital, following the
manufacturer’s instructions. The cut-off values were set at 1.9 ng/
mL and 3.0 ng/mL accordingly [17]. The CA125 level was measured
by radioimmunoassay at the same laboratory. The cut-off values for
CA125 were set at 35 U/mL and 100 U/mL.
Statistical analysis
SPSS version 12.0 (SPSS, Chicago, IL, USA) was used for man-
agement of the database and statistical analysis. Comparisons of
Fig. 1. The KaplaneMeier disease-free survival curves of preoperative serum cyto-
keratin19 fragment (Cyfra 21-1) levels divided at 3.0 ng/mL in epithelial ovarian
cancer; p ¼ 0.001 using the log rank test.
Fig. 2. The KaplaneMeier overall survival curves of preoperative serum cytokeratin19
fragment (Cyfra 21-1) levels divided at 3.0 ng/mL in epithelial ovarian cancer;
p ¼ 0.007 using the log rank test.
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method (one-way ANOVA). It analyses with group as a ﬁxed factor
used to assess. The cumulative probability of survival was assessed
using the KaplaneMeier method, and survival curves were
compared with the log rank test. The univariable analyses of
resistance to platinum and outcome were performed with the bi-
nary logistic regression method. Multivariable analyses of survival
were carried out using the Cox proportional hazards regression
model. A p value < 0.05 was considered to be signiﬁcant.Results
Correlations between mean serum levels of Cyfra 21-1 and
clinicopathologic parameters
The ages of the 42 patients ranged from 19 years to 75 years,
with a median of 50 years. The histology included 14 serous-typeTable 3
The correlations between clinicopathologic factors and outcome variables.
Outcome variable Cyfra 21-1 CA125 Age Ascites H
P-resistance 0.030 0.706 0.065 0.152 0
Recurrence 0.027 0.752 0.054 0.576 0
Death 0.043 0.858 0.096 0.781 0
CA ¼ cancer antigen; Cyfra 21-1 ¼ cytokeratin19 fragment; P-resistance ¼ cisplatin resicancers, six mucinous-type cancers, 13 endometrioid-type cancer,
ﬁve clear cell-type cancers, and four undifferentiated-type cancers.
The mean serum level of preoperative Cyfra 21-1 of the 42 EOC
patients was 12.06 ng/mL (range, 0.34e79.38 ng/mL).
The correlations between the mean levels of Cyfra 21-1 and the
clinicopathologic parameters are shown in Table 1. The preopera-
tive serum CA125 levels of 34 of these 42 patients were available for
reference. The mean value was 1178.23 U/mL (range, 15e7828 U/
mL). A higher level of CA125 was found in the younger group,
although there was no association between Cyfra 21-1 levels and
age. The serum levels of both Cyfra 21-1 and CA125 were signiﬁ-
cantly higher in patients with serous cell type, positive lymph
nodes, and resistance to chemotherapy. In addition, Cyfra 21-1
indicated the achievability of optimal surgery, recurrence, and
mortality. Neither marker was associated with grades of
differentiation.
Correlations between serum Cyfra 21-1 levels and survival
Using the cut-off values of 1.9 ng/mL and 3.0 ng/mL for Cyfra 21-
1, the positive rates for EOC were 71.4% (30/42) and 54.8% (23/42),
respectively. A preoperative Cyfra 21-1 level > 1.9 ng/mL did not
indicate poor survival relative to either DFS or OS (Table 2). How-
ever, using 3.0 ng/mL as a cut-off value, patients with an elevated
Cyfra 21-1 level had signiﬁcantly shorter DFS (p ¼ 0.001) and OS
(p ¼ 0.007) (Figs. 1 and 2). Using 35 IU/mL and 100 IU/mL as cut-off
values, the positive rates for CA125 were 88.2% (30/34) and 73.5%
(25/34), respectively. Higher CA125 levels had no signiﬁcantly
different effect on either DFS or OS.
Correlations between Cyfra 21-1 and platinum resistance, mortality,
and survival
Univariable analysis showed that elevated Cyfra 21-1 levels
(3.0 ng/mL), poor differentiation, and retroperitoneal metastasis
were signiﬁcantly associated with platinum resistance and mor-
tality (Table 3). Furthermore, multivariable analysis showed that
elevated serum Cyfra 21-1 (3.0 ng/mL) was signiﬁcantly associ-
ated with poor DFS (risk ratio ¼ 3.59, 95% CI ¼ 1.02e13.08,
p¼ 0.048) and OS (risk ratio¼ 3.31, 95% CI¼ 1.06e10.76, p¼ 0.040;
Table 4). However, an elevated serum CA125 level (35 U/mL) was
not signiﬁcant in either univariable or multivariable analysis.
Discussion
Cytokeratins are expressed by all epithelial cells. Expression of
cytokeratin is altered during epithelial differentiation, is important
for modulation and control of cell-cycle regulation, tumor cell
motility, and apoptosis [36]. CK19, a smaller and more acidic type 1
cytokeratin, is expressed in most simple epithelial cells and their
malignant counterparts. The CK19 fragment, Cyfra 21-1, with
epitope sequences of 311e335 and 346e367, is released into the
serum from proliferating cells during the late S and G2 phases [36].
Based on its differential expression in normal and malignant
epithelium, Cyfra 21-1 has been evaluated as a hopeful marker for
many cancers [37,38].istology Grading Lymph Nodes metastasis Optimal surgery
.259 0.038 0.006 0.324
.024 0.004 0.123 0.080
.896 0.004 0.030 0.297
stance.
Table 4
Multivariable analyses of prognostic factors for survival.
Prognostic factor Disease-free Survival Overall Survival
HR 95% CI pa HR 95% CI pa
Cyfra 21-1 3.59 (1.02e13.08) 0.048 3.37 (1.06e10.76) 0.040
CA125 0.55 (0.14e2.19) 0.402 1.22 (0.34e4.45) 0.757
Histology 1.14 (0.94e1.39) 0.189 1.01 (0.56e2.98) 0.860
Grading 1.33 (0.62e2.86) 0.455 1.58 (0.81e3.31) 0.176
Optimal surgery 1.06 (0.29e4.13) 0.883 1.09 (0.84e1.44) 0.502
Nodal metastasis 1.10 (0.94e1.54) 0.149 1.48 (1.06e2.07) 0.020
CA¼ cancer antigen; CI¼ conﬁdence interval; Cyfra 21-1¼ cytokeratin19 fragment;
HR ¼ hazard ratio.
a The p value was calculated using the Cox proportional hazards method.
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the 42 patients with EOC was only 12.06 ng/mL, with a range of
0.34e79.38 ng/mL. This reveals a possible limitation in monitoring
disease, because at this level the signiﬁcance of ﬂuctuated values in
low-level positivity would be difﬁcult to determine. By contrast,
serum Cyfra 21-1 has demonstrated the advantage of no age dif-
ference, so the data might not be confused by the occurrence of
many young age-related events, such as vaginal bleeding endo-
metriosis and pelvic inﬂammatory diseases [39].
In this prognostic study, Cyfra 21-1 showed consistent effects in
many aspects. First of all, the mean serum Cyfra 21-1 levels were
signiﬁcantly higher in the poor prognosis groups, including those
with the presence of ascites, retroperitoneal lymph node metas-
tasis, failure of optimal surgery, resistance to chemotherapy,
recurrence, and mortality. Second, an elevated serum level of Cyfra
21-1 (>3 ng/mL) was an independent prognostic factor for poor
DFS and OS in a multivariable analysis.
However, serum CA125 in this study was not associated with
either recurrence or mortality; further adjusting the cut-off levels
of CA125 from 35U/mL to 100 U/mL did not improve the prognostic
value. This ﬁnding echoes that of other reports, that the initial
preoperative serum CA125 level does not reﬂect survival for EOC
patients, although it is still the “gold standard” tool in the moni-
toring of diseases after treatment. To have survival signiﬁcance,
serum CA125 should be conﬁned to some complex estimations,
such as counting half-life, and testing prechemotherapy or at 8
weeks after surgery [7].
Overcoming resistance to chemotherapy is one of the critical
factors for prognosis, and resistance to platinum, especially, is the
milestone for successful treatment of women with EOC [40]. In
this study, through both univariable and multivariable analyses,
we showed that an elevated serum Cyfra 21-1 level was associated
with platinum resistance. Gadducci et al [28] had similar ﬁndings
when using second-look laparotomy for veriﬁcation of neoplasms.
Also, there is some in vitro evidence to suggest that cytokeratins
could exert drug resistance. In our previous in vitro study,
diminished expression of CK19 in cervical cancer cells after
treatment with a monoclonal antibody against CK19 resulted in an
increase in cytotoxicity to cisplatin or vinblastine of at least 15-
fold [41]. Other researchers used cytokeratin transfection and
other methods to demonstrate this rarely-noticed mechanism of
drug resistance [42].
In conclusion, the serum Cyfra 21-1 level was signiﬁcantly
correlated with many prognostic factors, including recurrence and
survival. It was an independent survival factor as shown in
multivariable analysis. The association of Cyfra 21-1 with response
to chemotherapy indicates an issue of both academic and clinical
interest that may be useful in tailoring chemotherapy in the
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